Novel Lung Functional Imaging for Personalized Radiotherapy

Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - 80
Start Date:September 2014
End Date:January 2020
Contact:Tokihiro Yamamoto, Ph.D.

Use our guide to learn which trials are right for you!

The primary objective of this study is to assess the safety and feasibility of personalized
radiotherapy with four-dimensional (4D) computed tomography (CT)-based pulmonary ventilation
imaging, which selectively avoids irradiating highly-functional lung regions.

In this clinical trial, the investigators will assess the safety and feasibility of 4D CT
ventilation image-guided personalized radiotherapy. The investigators will deliver
personalized radiotherapy treatments that selectively avoid irradiating highly-functional
lung regions for lung cancer patients, and follow up patients to assess the safety and
feasibility. The primary hypothesis to be tested is: 4D CT ventilation image-guided
personalized radiotherapy can be delivered safely for lung cancer.

Inclusion Criteria:

- Primary lung cancer or metastatic disease to the lungs to be treated with either
conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic
ablative radiotherapy (SABR).

- Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age.
There are no gender or ethnic restrictions.

- Concurrent chemotherapy is allowed, but not required.

- Life expectancy with treatment should be ≥6 months in the estimation of the treating

- Zubrod performance status ≤2

- Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500;
LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50

- Patient must be able to provide study specific informed consent prior to study entry.

Exclusion Criteria:

- Prior radiotherapy for thoracic cancer or other malignancy leading to any overlap of
planned radiotherapy fields.

- For patients undergoing definitive CFRT, patients with distant metastatic disease are
not eligible.

- For patients undergoing SABR, both early stage primary lung cancer patients and those
with limited metastatic disease to the lungs are eligible; however, patients with
oligometastatic disease should have a controlled primary and no more than one other
involved organ system.

- Children (<18 years of age), pregnant women, University of California employees or
students, or prisoners will be excluded from this study.
We found this trial at
2315 Stockton Blvd.
Sacramento, California 95817
(916) 734-2011
Phone: 916-734-0604
University of California, Davis Medical Center UC Davis Medical Center serves a 65,000-square-mile area that...
Sacramento, CA
Click here to add this to my saved trials